Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Neoplasm Drug Resistance. Found 49 abstracts

no pagination
Ablain J, Xu M, Rothschild H, Jordan RC, Mito JK, Daniels BH, Bell CF, Joseph NM, Wu H, Bastian BC, Zon LI, Yeh I. Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. Science (New York, NY). 2018 Nov 30;362(6418):1055-60.   PMCID: PMC6475924
von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol. 2018 Jan 10;36(2):136-43.   PMCID: PMC6553810
Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Nov 15;123(22):4411-8.
Hou P, Wu C, Wang Y, Qi R, Bhavanasi D, Zuo Z, Dos Santos C, Chen S, Chen Y, Zheng H, Wang H, Perl A, Guo D, Huang J. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. Cancer Res. 2017 Aug 15;77(16):4402-13.   PMCID: PMC5559306
Lu H, Liu S, Zhang G, Bin W, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 Oct 05;550(7674):133-6.   PMCID: PMC5891348
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11;7(41):67495-506.   PMCID: PMC5341892
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15;75(8):1668-74.   PMCID: PMC4541796
Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res. 2015 Jan 15;17:6.   PMCID: 4336497
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T. Preclinical efficacy for AKT targeting in clear cell carcinoma of the ovary. Molecular Cancer Research. 2015 Apr;13(4):795-806.   PMCID: PMC4398602
Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015 Oct;16(13):e510-21.
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun;20(11):3023-32.   PMCID: Pmc4049169
Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical pharmacology. 2014 May;89(1):52-61.   PMCID: Pmc3983711
Teijaro CN, Munagala S, Zhao S, Sirasani G, Kokkonda P, Malofeeva EV, Hopper-Borge E, Andrade RB. Synthesis and biological evaluation of pentacyclic strychnos alkaloids as selective modulators of the ABCC10 (MRP7) efflux pump. Journal of medicinal chemistry. 2014 Dec 26;57(24):10383-90.   PMCID: PMC4281106
Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46.
von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.   PMCID: Pmc4045341
Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu QS, Singh S, Yang DH, Talele TT, Ambudkar SV, Chen ZS. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One. 2011 Jan;6(4):e19329.   PMCID: PMC3084276
Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Science signaling. 2010 Jan;3(140):ra67.   PMCID: PMC2950064
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Neoplasm Drug Resistance

Neoplasm Drug Resistance drug therapy metabolism genetics therapeutic use Female antagonists & inhibitors Antineoplastic Agents Male drug effects Signal Transduction pharmacology Adult Middle Aged Aged Protein Kinase Inhibitors Mutation pathology administration & dosage Disease-Free Survival Antineoplastic Combined Chemotherapy Protocols Mice chemistry adverse effects Tumor Cell Line adverse 80 and over Aged Neoplastic Gene Expression Regulation effects Local Neoplasm Recurrence analogs & derivatives enzymology physiology Molecular Targeted Therapy Non-Small-Cell Lung Carcinoma Mitogen-Activated Protein Kinase Kinases Maximum Tolerated Dose Colorectal Neoplasms Tumor Biomarkers Retreatment Proto-Oncogene Proteins c-kit mortality Lung Neoplasms Pyridines Nude Mice ras Proteins Paclitaxel therapy Apoptosis secondary Neoplasms blood TOR Serine-Threonine Kinases Receptor Protein-Tyrosine Kinases Proto-Oncogene Proteins c-akt Neoplasm Proteins Treatment Outcome Gene Knockdown Techniques Mitogen-Activated Protein Kinases methods Ovarian Neoplasms Cell Proliferation Monoclonal Antibodies-Humanized analysis Adenosine Triphosphatases Melanoma Xenograft Model Antitumor Assays Tumor Microenvironment Phenotype derivatives Kaplan-Meier Estimate Phospholipid Transfer Proteins Diarrhea Alkaloids Inhibitor of Apoptosis Proteins Genomics Cimp Proto-Oncogene Proteins Lymphoma Telatinib Clear Cell Adenocarcinoma Platelet-Derived Growth Factor alpha Receptor basic helix-loop-helix (MYC) Strychnos Enzyme Activation Type 5 Cyclic Nucleotide Phosphodiesterases DNA Methylation Fatigue Skin Neoplasms Protein Kinase C Chemoradiotherapy Survival Analysis Hypotension HCT116 Cells MAP Kinase Signaling System Camptothecin surgery Intracellular Signaling Peptides and Proteins Small Interfering RNA Cytotoxins Cisplatin Phenylurea Compounds Molecular Models JNK Mitogen-Activated Protein Kinases Breast Neoplasms IGF Type 1 Receptor Hep G2 Cells Fallopian Tube Neoplasms non-Hodgkin lymphoma Small Molecule Libraries azacitidine P-Glycoprotein use Immunohistochemistry Piperazines Capecitabine Salvage Therapy Proportional Hazards Models Differentiation Antigens Hematopoietic Stem Cell Transplantation Ubiquitin-Protein Ligases beta Catenin Pyridazines Proto-Oncogene Proteins c-bcl-2 colorectal cancer Young Adult Multidrug Resistance-Associated Proteins Imidazoles Protein Transport Vimentin Phosphatidylinositol 3-Kinases Cultured Cells therapeutic Experimental Melanoma Myeloid Leukemia-Acute myc Genes Phosphorylation Brain Neoplasms Epidermal Growth Factor Receptor HEK293 Cells Cell Death Blood-Brain Barrier Multiprotein Complexes STAT2 Transcription Factor Retrospective Studies hematopoietic cell transplantation (HCT) ATP-Binding Cassette Transporters Sulfones Gastrointestinal Stromal Tumors Prognosis
Last updated on Friday, January 03, 2020